Technical Analysis for LIXT - Lixte Biotechnology Holdings, Inc.

Grade Last Price % Change Price Change
D 2.4 -9.43% -0.25
LIXT closed down 9.43 percent on Monday, April 19, 2021, on 6 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical LIXT trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Expansion Breakdown Bearish Swing Setup -9.43%
Wide Bands Range Expansion -9.43%
Below Lower BB Weakness -9.43%
Lower Bollinger Band Touch Weakness -9.43%
Older End-of-Day Signals for LIXT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 13 hours ago
Down 10% about 13 hours ago
Down 5% about 18 hours ago
Down 3% about 18 hours ago
Down 2 % about 18 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Lixte Biotechnology Holdings, Inc. Description

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases; and LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and study with the National Cancer Institute. The company was founded in 2005 and is based in East Setauket, New York.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Development Treatment Of Cancer Cancers Drug Discovery X Ray Biomarker Degenerative Disease Degenerative Diseases Sarcoma Metabolic Disease Metabolic Diseases Neurodegenerative Diseases Cancer Center Immune Checkpoint Treatment Of Cancers National Cancer Institute Biomarker Technology Gaucher's Disease Vascular And Metabolic Diseases

Is LIXT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 7.19
52 Week Low 0.0
Average Volume 1,311,231
200-Day Moving Average 2.24
50-Day Moving Average 3.58
20-Day Moving Average 3.22
10-Day Moving Average 3.00
Average True Range 0.31
ADX 19.67
+DI 19.05
-DI 28.11
Chandelier Exit (Long, 3 ATRs ) 3.19
Chandelier Exit (Short, 3 ATRs ) 3.31
Upper Bollinger Band 3.92
Lower Bollinger Band 2.52
Percent B (%b) -0.09
BandWidth 43.40
MACD Line -0.26
MACD Signal Line -0.18
MACD Histogram -0.0783
Fundamentals Value
Market Cap 29.7 Million
Num Shares 12.4 Million
EPS -0.04
Price-to-Earnings (P/E) Ratio -63.16
Price-to-Sales 0.00
Price-to-Book 322.42
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.76
Resistance 3 (R3) 2.79 2.71 2.70
Resistance 2 (R2) 2.71 2.61 2.69 2.68
Resistance 1 (R1) 2.55 2.56 2.51 2.52 2.66
Pivot Point 2.47 2.47 2.45 2.45 2.47
Support 1 (S1) 2.31 2.37 2.27 2.28 2.14
Support 2 (S2) 2.23 2.32 2.21 2.12
Support 3 (S3) 2.07 2.23 2.10
Support 4 (S4) 2.04